Haematology and Inherited Blood Disorders
Clinical research activity includes transfusion-dependent beta-thalassemia, with attention to restoring transfusion independence and improving outcomes in patients with chronic haemoglobin disorders.
- Beta-thalassemia
- Transfusion dependence
- Haematopoietic stem cell therapy
The sponsor’s work in this area is centred on gene therapy approaches for inherited anaemias and related blood-cell replacement strategies.
Paediatric Genetic Disorders
Research also focuses on autosomal recessive osteopetrosis linked to TCIRG1 mutations, a severe inherited condition affecting bone remodelling and the function of haematopoietic progenitor cells.
- Autosomal recessive osteopetrosis
- TCIRG1-related disease
- Paediatric rare disease
This area reflects interest in genetic correction and cell-based treatment for children with rare, life-limiting disorders.
Ex Vivo Cell and Gene Therapy
Trial activity involves autologous CD34+ haematopoietic stem and progenitor cells, lentiviral vector delivery, and ex vivo expansion for inherited haematological and skeletal disease.
- Autologous stem cell products
- Lentiviral vector gene transfer
- Ex vivo cell engineering
The research landscape highlights advanced cellular therapy platforms designed to modify patient-derived cells for therapeutic use.
Paediatric and Adult Rare-Disease Care
The sponsor is engaged in studies spanning both paediatric and adult populations, with a focus on specialised treatment pathways for rare inherited conditions managed in a hospital-based setting.
- Paediatric patients
- Adult patients
- Rare disease management
These trials are aligned with clinical interests in disorders requiring highly specialised translational medicine and advanced haematology expertise.
